AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Pathstone Holdings LLC

Pathstone Holdings LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 370,229 shares of the company's stock after acquiring an additional 22,995 shares during the quarter. Pathstone Holdings LLC's holdings in AstraZeneca were worth $24,259,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. Moody National Bank Trust Division lifted its holdings in shares of AstraZeneca by 20.0% during the 4th quarter. Moody National Bank Trust Division now owns 4,556 shares of the company's stock valued at $299,000 after acquiring an additional 758 shares in the last quarter. Wallace Advisory Group LLC acquired a new position in AstraZeneca in the 4th quarter worth $171,000. Accurate Wealth Management LLC lifted its holdings in AstraZeneca by 3.4% in the 4th quarter. Accurate Wealth Management LLC now owns 8,463 shares of the company's stock worth $567,000 after buying an additional 275 shares in the last quarter. Pines Wealth Management LLC acquired a new position in AstraZeneca in the 4th quarter worth $378,000. Finally, Community Trust & Investment Co. lifted its holdings in AstraZeneca by 5.1% in the 4th quarter. Community Trust & Investment Co. now owns 183,523 shares of the company's stock worth $12,024,000 after buying an additional 8,903 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on AZN shares. Morgan Stanley started coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of "Buy" and an average target price of $88.00.

AstraZeneca Stock Up 1.3%

Shares of AstraZeneca stock traded up $0.85 during trading on Friday, reaching $68.81. The company had a trading volume of 3,742,544 shares, compared to its average volume of 5,185,747. The company has a market cap of $213.40 billion, a price-to-earnings ratio of 30.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The firm's fifty day moving average is $70.46 and its 200-day moving average is $69.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.06 EPS. On average, analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.